S
Synlogic
Biotech & Life Sciences · Cambridge, United States · Founded 2014 · IPO 2015
Medicines to perform metabolic functions to treat diseases throughout the body MoreLess
Synlogic, Inc. operates in the biotechnology sector, focusing on the development of synthetic biology-based therapeutics. The company engineers bacteria to perform specific functions within the human body, targeting complex diseases that are difficult to treat with traditional methods. Synlogic's primary clients include healthcare providers and pharmaceutical companies. The company operates in the global healthcare market, leveraging its proprietary technology to create novel treatments. Synlogic generates revenue through research and development partnerships, grants, and potential future product sales. Key products in development include SYNB1891, aimed at stimulating immune responses in challenging tumors. Keywords: synthetic biology, bacterial therapeutics, complex diseases, immune response, healthcare, biotechnology, engineered bacteria, R&D partnerships, SYNB1891, pharmaceutical.
Talent graph
Synlogic's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Synlogic has talent and traffic
team presence
Market sentiment
What the market is saying about Synlogic
An AI-synthesized read of the highest-engagement posts about Synlogic on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synlogic on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.